Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-900-2660
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$15.75 million
Profitability
Miscellaneous
Employees72
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions
What is Arcturus Therapeutics' stock symbol?
Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."
How were Arcturus Therapeutics' earnings last quarter?
Arcturus Therapeutics Ltd (NASDAQ:ARCT) posted its quarterly earnings results on Thursday, August, 15th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.46. The biotechnology company had revenue of $10.15 million for the quarter, compared to analysts' expectations of $4.01 million. Arcturus Therapeutics had a negative return on equity of 112.75% and a negative net margin of 50.32%. View Arcturus Therapeutics' Earnings History.
When is Arcturus Therapeutics' next earnings date?
What price target have analysts set for ARCT?
5 equities research analysts have issued 12-month target prices for Arcturus Therapeutics' shares. Their predictions range from $18.00 to $18.00. On average, they expect Arcturus Therapeutics' share price to reach $18.00 in the next year. This suggests a possible upside of 86.9% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics.
What is the consensus analysts' recommendation for Arcturus Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics.
What are Wall Street analysts saying about Arcturus Therapeutics stock?
Here are some recent quotes from research analysts about Arcturus Therapeutics stock:
- 1. According to Zacks Investment Research, "Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. " (10/8/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.2%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently." (4/5/2019)
Has Arcturus Therapeutics been receiving favorable news coverage?
Media headlines about ARCT stock have trended somewhat negative this week, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Arcturus Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Arcturus Therapeutics.
Are investors shorting Arcturus Therapeutics?
Arcturus Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totalling 76,800 shares, an increase of 15.1% from the August 30th total of 66,700 shares. Based on an average daily volume of 103,500 shares, the short-interest ratio is currently 0.7 days. Approximately 1.1% of the shares of the company are sold short. View Arcturus Therapeutics' Current Options Chain.
Who are some of Arcturus Therapeutics' key competitors?
Some companies that are related to Arcturus Therapeutics include DiaMedica Therapeutics (DMCAF), Catalyst Pharmaceuticals (CPRX), MacroGenics (MGNX), OrganiGram (OGI), IGM Biosciences (IGMS), Flexion Therapeutics (FLXN), TG Therapeutics (TGTX), Arvinas (ARVN), Milestone Pharmaceuticals (MIST), Basilea Pharmaceutica (BPMUF), Akebia Therapeutics (AKBA), INDIVIOR PLC/S (INVVY), Retrophin (RTRX), BioDelivery Sciences International (BDSI) and Viking Therapeutics (VKTX).
What other stocks do shareholders of Arcturus Therapeutics own?
Who are Arcturus Therapeutics' key executives?
Arcturus Therapeutics' management team includes the folowing people:
- Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)
- Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)
- Mr. Andrew H. Sassine, CFO & Director (Age 55)
- Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
- Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller
Who are Arcturus Therapeutics' major shareholders?
Arcturus Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Dfpg Investments Inc. (3.23%) and We Are One Seven LLC (0.10%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Institutional Ownership Trends for Arcturus Therapeutics.
Which institutional investors are buying Arcturus Therapeutics stock?
ARCT stock was acquired by a variety of institutional investors in the last quarter, including Dfpg Investments Inc. and We Are One Seven LLC. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Magda Marquet and Peter C Farrell. View Insider Buying and Selling for Arcturus Therapeutics.
How do I buy shares of Arcturus Therapeutics?
Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arcturus Therapeutics' stock price today?
One share of ARCT stock can currently be purchased for approximately $9.63.
How big of a company is Arcturus Therapeutics?
Arcturus Therapeutics has a market capitalization of $137.47 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics.
What is Arcturus Therapeutics' official website?
How can I contact Arcturus Therapeutics?
Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]
MarketBeat Community Rating for Arcturus Therapeutics (NASDAQ ARCT)
MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days.
